Sopharma AD has issued a correction to previous notifications regarding the sale of its treasury shares, citing a technical mistake in the reported figures. The company, which is listed on both the Bulgarian Stock Exchange and the Warsaw Stock Exchange, clarified changes in the number of treasury shares following transactions conducted at the end of July and early August 2025.
In its announcement, Sopharma AD stated that for the notification dated July 31, 2025, “The total number of treasury shares after this transaction is 26 060 100 representing 4.83% of the share capital of the Company.” This should be corrected to: “The total number of treasury shares after this transaction is 26 053 100 representing 4.83% of the share capital of the Company.”
For the notification as of August 1, 2025, where it was previously stated: “The total number of treasury shares after this transaction is 26 057 700 representing 4.83% of the share capital of the Company,” it should now read: “The total number of treasury shares after this transaction is 26 050 700 representing 4.83% of the share capital of the Company.”
Finally, for August 4, 2025, Sopharma AD had announced: “The total number of treasury shares after this transaction is 26 047 200 representing 4.83% of the share capital of the Company.“ This figure has been corrected to: “The total number of treasury shares after this transaction is 26 040 200 representing 4.83% of the share capital of the Company.”
These corrections are made in accordance with Article 17 of Regulation (EU) No.596/2014.
